Related Experiment Video
Updated: May 27, 2025

Author Spotlight: Enhancing Women's Chronic Pelvic Pain Management Through Acupoint Catgut Embedding
Published on: May 3, 2024
Treatment rationale in nutcracker syndrome with concurrent pelvic congestion syndrome
Dominik A Steffen1, Arash Najafi2, Georgios Festas3
1Department of Radiology and Nuclear Medicine, Cantonal Hospital Winterthur, Brauerstrasse 15, Winterthur, CH-8401, Switzerland. dominik.steffen@ksw.ch.
Abstract:
The optimal management strategy of nutcracker syndrome is debated, especially in the setting of concurrent pelvic congestion syndrome. In this article, we describe our treatment algorithm as illustrated by four different case scenarios. In our experience, renocaval pressure gradients are often inconclusive, but evaluation of the left renal vein waveform as well as a "test PTA" with evidence of a waist in the balloon can be helpful in unmasking a relevant stenosis. We consider nutcracker syndrome not to be a contraindication for ovarian vein embolization. Decision for simultaneous or sequential stenting should be based on angiographic findings and clinical course.
More Related Videos
03:50Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
05:36Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
Published on: October 4, 2024
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Irritable Bowel Syndrome III: Medical and Nursing Management
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists